Valuation: Atossa Therapeutics, Inc.

Market Cap 2.14Cr 1.87Cr 1.73Cr 1.59Cr 3Cr 206.49Cr 3.07Cr 21Cr 8.13Cr 101.13Cr 8.05Cr 7.88Cr 348.14Cr P/E 2026 *
-0.57x
P/E 2027 * -0.72x
Enterprise Value 2.14Cr 1.87Cr 1.73Cr 1.59Cr 3Cr 206.49Cr 3.07Cr 21Cr 8.13Cr 101.13Cr 8.05Cr 7.88Cr 348.14Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-0.60%
1 week+5.06%
Current month+29.02%
1 month+23.88%
3 months-57.29%
6 months-73.01%
Current year-71.86%
1 week 2.22
Extreme 2.225
2.5
1 month 1.7
Extreme 1.7
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
68.55
10 years 1.7
Extreme 1.7
806.76
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Founder

10,000 0.1161%
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%+5.06%-80.28%-84.49% 2.14Cr
-0.67%-4.04%+0.57%+2.24% 4.92TCr
+0.18%-0.39%+386.06%+588.97% 3.96TCr
+1.17%+4.46%+5.93%+61.54% 3.47TCr
-0.99%-0.76%+28.41%-8.52% 3.44TCr
+0.06%+0.34%+2.38%+34.47% 2.71TCr
+0.13%-3.49% - - 1.62TCr
-0.30%-0.09%+72.42%+116.45% 1.54TCr
+0.11%+1.29%+14.32%+17.10% 1.41TCr
-0.84%+1.36%+18.43%-31.23% 1.3TCr
Average -0.19%+0.53%+49.80%+77.39% 2.44TCr
Weighted average by Cap. -0.16%-0.18%+79.61%+122.31%

Financials

2026 *2027 *
Net sales - -
Net income -3.74Cr -3.27Cr -3.02Cr -2.78Cr -5.24Cr -360.1Cr -5.36Cr -36Cr -14Cr -176.36Cr -14Cr -14Cr -607.12Cr -3.93Cr -3.44Cr -3.17Cr -2.92Cr -5.51Cr -378.59Cr -5.63Cr -38Cr -15Cr -185.42Cr -15Cr -14Cr -638.3Cr
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
20/26/20 $2.480 -0.40% 1,379
17/26/17 $2.490 +4.18% 47,873
16/26/16 $2.390 -2.05% 68,960
15/26/15 $2.440 +7.96% 97,154
14/26/14 $2.260 -5.83% 1,57,797
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.490USD
Average target price
22.00USD
Spread / Average Target
+783.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock